AU2015349866B2 - 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of GPR139 - Google Patents

4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of GPR139 Download PDF

Info

Publication number
AU2015349866B2
AU2015349866B2 AU2015349866A AU2015349866A AU2015349866B2 AU 2015349866 B2 AU2015349866 B2 AU 2015349866B2 AU 2015349866 A AU2015349866 A AU 2015349866A AU 2015349866 A AU2015349866 A AU 2015349866A AU 2015349866 B2 AU2015349866 B2 AU 2015349866B2
Authority
AU
Australia
Prior art keywords
triazin
oxobenzo
acetamide
ethyl
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015349866A
Other languages
English (en)
Other versions
AU2015349866A1 (en
Inventor
Stephen Hitchcock
Betty Lam
Holger Monenschein
Holly REICHARD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2015349866A1 publication Critical patent/AU2015349866A1/en
Application granted granted Critical
Publication of AU2015349866B2 publication Critical patent/AU2015349866B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2015349866A 2014-11-20 2015-11-19 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of GPR139 Active AU2015349866B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462082539P 2014-11-20 2014-11-20
US62/082,539 2014-11-20
US201562184729P 2015-06-25 2015-06-25
US62/184,729 2015-06-25
PCT/US2015/061607 WO2016081736A1 (en) 2014-11-20 2015-11-19 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of gpr139

Publications (2)

Publication Number Publication Date
AU2015349866A1 AU2015349866A1 (en) 2017-06-15
AU2015349866B2 true AU2015349866B2 (en) 2020-12-03

Family

ID=55022667

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015349866A Active AU2015349866B2 (en) 2014-11-20 2015-11-19 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of GPR139

Country Status (40)

Country Link
US (5) US9556130B2 (enExample)
EP (2) EP3221298B1 (enExample)
JP (2) JP6637501B2 (enExample)
KR (1) KR102582021B1 (enExample)
CN (2) CN112062730B (enExample)
AU (1) AU2015349866B2 (enExample)
CA (1) CA2968242C (enExample)
CL (1) CL2017001292A1 (enExample)
CO (1) CO2017005959A2 (enExample)
CR (1) CR20170275A (enExample)
CY (2) CY1122613T1 (enExample)
DK (2) DK3221298T3 (enExample)
DO (1) DOP2017000120A (enExample)
EA (1) EA033728B1 (enExample)
EC (1) ECSP17038999A (enExample)
ES (2) ES2734735T3 (enExample)
GE (2) GEP20196961B (enExample)
HR (2) HRP20212009T1 (enExample)
HU (2) HUE057451T2 (enExample)
IL (1) IL252311B (enExample)
JO (1) JO3719B1 (enExample)
LT (2) LT3221298T (enExample)
MA (1) MA40993B1 (enExample)
MD (1) MD3221298T2 (enExample)
MX (1) MX378158B (enExample)
MY (1) MY187423A (enExample)
NZ (1) NZ732208A (enExample)
PE (1) PE20170899A1 (enExample)
PH (1) PH12017500920B1 (enExample)
PL (2) PL3536324T3 (enExample)
PT (2) PT3221298T (enExample)
RS (2) RS59078B1 (enExample)
SG (1) SG11201704002UA (enExample)
SI (2) SI3221298T1 (enExample)
SM (2) SMT201900355T1 (enExample)
TN (1) TN2017000196A1 (enExample)
TW (1) TWI684590B (enExample)
UA (1) UA120375C2 (enExample)
UY (1) UY36406A (enExample)
WO (1) WO2016081736A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3719B1 (ar) * 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139
US12042496B2 (en) 2018-10-16 2024-07-23 The University Of Florida Research Foundation, Incorporated Methods related to opioid therapeutics
WO2020097609A1 (en) * 2018-11-09 2020-05-14 Blackthorn Therapeutics, Inc. Gpr139 receptor modulators
TWI873185B (zh) * 2019-09-16 2025-02-21 日商武田藥品工業股份有限公司 唑稠合之嗒-3(2h)-酮衍生物
WO2021127459A1 (en) * 2019-12-20 2021-06-24 Blackthorn Therapeutics, Inc. Gpr139 receptor modulators
JP7697974B2 (ja) * 2020-05-08 2025-06-24 武田薬品工業株式会社 Ｇｐｒ１３９アゴニストの置換ベンゾトリアジノン代謝物
US20230310441A1 (en) * 2020-09-21 2023-10-05 Takeda Pharmaceutical Company Treatment for schizophrenia
US11760788B2 (en) 2021-03-02 2023-09-19 Pathways Neuro Pharma, Inc. Neuroreceptor compositions and methods of use
CN116693536A (zh) * 2022-03-01 2023-09-05 上海科技大学 吡咯并三嗪酮类化合物、含其的药物组合物、其制备方法及其应用
CN116693545A (zh) * 2022-03-01 2023-09-05 上海科技大学 噻吩并含氮杂环类化合物、含其的药物组合物、其制备方法及其应用
CN117986183A (zh) * 2022-10-28 2024-05-07 浙江友宁生物医药科技有限公司 一种gpr139受体激动剂、其制备方法及其应用
WO2024102802A1 (en) * 2022-11-11 2024-05-16 Takeda Pharmaceutical Company Limited Zelatriazin for the treatment of depression
WO2025119351A1 (zh) * 2023-12-08 2025-06-12 深圳湾实验室 Gpr139激动剂
CN117815217B (zh) * 2023-12-29 2026-07-10 郑州大学第三附属医院(河南省妇幼保健院) 一种苯甲酰胺衍生物改善认知功能障碍的用途
WO2025162441A1 (zh) * 2024-02-02 2025-08-07 上海科技大学 稠杂环类化合物与其制备方法、药物组合物及应用
CN121159462A (zh) * 2025-11-19 2025-12-19 杭州市第七人民医院(杭州市心理危机研究与干预中心) 喹唑啉酮类化合物及其在制备神经系统疾病药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090163545A1 (en) * 2007-12-21 2009-06-25 University Of Rochester Method For Altering The Lifespan Of Eukaryotic Organisms

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3794726A (en) * 1972-08-21 1974-02-26 Uniroyal Inc Inhibiting aggressive behavior with 1,2,3-benzotriazin-(3h)-one
EP0257102B1 (en) 1986-02-24 1997-11-19 Mitsui Petrochemical Industries, Ltd. Agents for treating neurophathy
ATE108791T1 (de) * 1987-11-04 1994-08-15 Beecham Group Plc Neue 4-oxobenzotriazine und 4-oxochinazoline.
CA2526506A1 (en) 2003-06-09 2004-12-16 Boehringer Ingelheim International Gmbh Inhibitors of papilloma virus
EP1651643A4 (en) 2003-07-31 2008-10-08 Irm Llc BICYCLIC COMPOUNDS AND COMPOSITIONS USED AS PDF INHIBITORS
FR2875805B1 (fr) 2004-09-27 2006-12-29 Genfit S A Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations
UY30048A1 (es) 2005-12-23 2007-07-31 Astrazeneca Ab Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
EP2139895A1 (en) * 2007-03-23 2010-01-06 F. Hoffmann-Roche AG Aza-pyridopyrimidinone derivatives
WO2011138265A2 (en) 2010-05-03 2011-11-10 Evotec Ag Indole and indazole derivatives as orexin receptor antagonists
EP2968240A2 (en) * 2013-03-14 2016-01-20 Janssen Pharmaceutica, N.V. Physiological ligands for gpr139
JO3719B1 (ar) * 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090163545A1 (en) * 2007-12-21 2009-06-25 University Of Rochester Method For Altering The Lifespan Of Eukaryotic Organisms

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
CAS Registry Number 1001630-69-8, STN Entry Date: 5 February 2008, N-[(3,4-dimethoxyphenyl)methyl]-4-oxo-1,2,3-benzotriazine-3(4H)-acetamide *
CAS Registry Number 1043204-06-3, STN Entry Date: 24 August 2008, N-methyl-4-oxo-N-(phenylmethyl)-1,2,3,-benzotriazine-3(4H)-acetamide *
CAS Registry Number 1043286-27-6, STN Entry Date: 24 August 2008, N-[1-(2,4-dichlorophenyl)ethyl]-4-oxo-1,2,3-benzotriazine-3(4H)-acetamide *
CAS Registry Number 1235085-25-2, STN Entry Date 5 August 2010, 4-oxo-N-[[2-(trifluoromethoxy)phenyl]methyl]-1,2,3-benzotriazine-3(4H)-acetamide *
CAS Registry Number 1314016-24-4, STN Entry Date: 28 July 2011, (αS)-N-[(3,4-dimethoxyphenyl)methyl]-α-methyl-4-oxo-1,2,3-benzotriazine-3(4H)-acetamide *
CAS Registry Number 1323657-53-9, STN Entry Date: 26 August 2011, α-methyl-N-[(4-methylphenyl)methyl]-4-oxo-1,2,3-benzotriazine-3(4H)-acetamide *
CAS Registry Number 1574302-61-6, STN Entry Date: 26 March 2014, N-[(2,6-difluorophenyl)methyl]-4-oxo-1,2,3-benzotriazine-3(4H)-acetamide *
CAS Registry Number 440331-93-1, STN Entry Date: 26 July 2002, N-[(2-chlorophenyl)methyl]-4-oxo-1,2,3-benzotriazine-3(4H)-acetamide *
CAS Registry Number 440331-96-4, STN Entry Date: 26 July 2002, N-[(2-methoxyphenyl)methyl]-4-oxo-1,2,3-benzotriazine-3(4H)-acetamide *
CAS Registry Number 440332-01-4, STN Entry Date: 26 July 2002, 4-oxo-N-(2-phenylethyl)-1,2,3-benzotriazine-3(4H)-acetamide *
CAS Registry Number 440332-02-5, STN Entry Date 26 July 2002, N-[2-(4-chlorophenyl)ethyl]-4-oxo-1,2,3-benzotriazine-3(4H)-acetamide *
CAS Registry Number 919725-54-5, STN Entry Date: 7 February 2007, N-[2-(4-methoxyphenyl)ethyl]-α-(1-methylethyl)-4-oxo-1,2,3-benzotriazine-3(4H)-acetamide *
CAS Registry Number 942888-50-8, STN Entry Date: 19 July 2007, 4-oxo-N-(1-phenylethyl)-1,2,3-benzotriazine-3(4H)-acetamide *
CAS Registry Number 942888-62-2, STN Entry Date: 19 July 2007, α-ethyl-4-oxo-N-(1-phenylethyl)-1,2,3-benzotriazine-3(4H)-acetamide *

Also Published As

Publication number Publication date
ECSP17038999A (es) 2017-10-31
KR20170084324A (ko) 2017-07-19
SMT202200142T1 (it) 2022-05-12
JP2020063285A (ja) 2020-04-23
HRP20212009T1 (hr) 2022-04-01
US20160145218A1 (en) 2016-05-26
US20170348319A1 (en) 2017-12-07
BR112017010311A2 (pt) 2017-12-26
MX2017006448A (es) 2017-09-12
NZ732208A (en) 2023-02-24
CO2017005959A2 (es) 2017-10-20
TW201625566A (zh) 2016-07-16
IL252311B (en) 2020-07-30
CN107108531A (zh) 2017-08-29
CA2968242C (en) 2022-11-08
CY1124929T1 (el) 2023-01-05
DK3536324T3 (da) 2021-10-25
CA2968242A1 (en) 2016-05-26
MD3221298T2 (ro) 2019-10-31
TN2017000196A1 (en) 2018-10-19
CL2017001292A1 (es) 2018-02-16
US10159677B2 (en) 2018-12-25
US10561662B2 (en) 2020-02-18
US20190070187A1 (en) 2019-03-07
MX378158B (es) 2025-03-10
RS59078B1 (sr) 2019-09-30
PH12017500920A1 (en) 2017-11-20
PE20170899A1 (es) 2017-07-12
US11173161B2 (en) 2021-11-16
EA033728B1 (ru) 2019-11-20
PL3221298T3 (pl) 2019-10-31
CN112062730B (zh) 2023-09-29
IL252311A0 (en) 2017-07-31
EP3221298B1 (en) 2019-04-03
CN107108531B (zh) 2020-10-20
GEAP201814515A (en) 2018-12-10
LT3221298T (lt) 2019-08-12
PT3536324T (pt) 2021-11-10
ES2734735T3 (es) 2019-12-11
UY36406A (es) 2016-06-30
JO3719B1 (ar) 2021-01-31
HUE044145T2 (hu) 2019-09-30
JP6637501B2 (ja) 2020-01-29
AU2015349866A1 (en) 2017-06-15
MY187423A (en) 2021-09-22
CY1122613T1 (el) 2021-05-05
DOP2017000120A (es) 2017-06-15
KR102582021B1 (ko) 2023-09-22
EP3536324B1 (en) 2021-10-06
HRP20191003T1 (hr) 2019-08-23
PT3221298T (pt) 2019-06-28
MA40993A (fr) 2017-09-27
US9556130B2 (en) 2017-01-31
SI3221298T1 (sl) 2019-10-30
GEP20196961B (en) 2019-03-25
US20170095480A1 (en) 2017-04-06
ES2897545T3 (es) 2022-03-01
HUE057451T2 (hu) 2022-05-28
LT3536324T (lt) 2021-12-10
DK3221298T3 (da) 2019-06-24
JP6918088B2 (ja) 2021-08-11
SMT201900355T1 (it) 2019-07-11
CN112062730A (zh) 2020-12-11
US9770450B2 (en) 2017-09-26
UA120375C2 (uk) 2019-11-25
TWI684590B (zh) 2020-02-11
SG11201704002UA (en) 2017-06-29
EA201791096A1 (ru) 2017-11-30
JP2017535559A (ja) 2017-11-30
PH12017500920B1 (en) 2017-11-20
PL3536324T3 (pl) 2022-02-07
WO2016081736A1 (en) 2016-05-26
US20200129518A1 (en) 2020-04-30
RS62563B1 (sr) 2021-12-31
MA40993B1 (fr) 2019-07-31
SI3536324T1 (sl) 2021-12-31
EP3221298A1 (en) 2017-09-27
EP3536324A1 (en) 2019-09-11
CR20170275A (es) 2017-10-30

Similar Documents

Publication Publication Date Title
US11173161B2 (en) 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139
JP7287952B2 (ja) アデノシン受容体アンタゴニストとしてのベンズイミダゾール誘導体
TW200817393A (en) Compounds and compositions as hedgehog pathway modulators
IL271149B1 (en) Compounds for modulating s1p1 activity and methods of using the same
TW200524878A (en) Gabanergic modulators
AU2003248907A1 (en) Treatment of neuropathic pain with 6H-pyrrolo[3,4-d]pyridazine compounds
JP2017534572A (ja) ＣａＭＫＩＩ阻害剤及びその使用
TW202444700A (zh) 作為sarm1抑制劑之經取代1h-吡唑-4-甲醯胺化物
HK40013780A (en) 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of gpr139
HK40013780B (en) 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of gpr139
HK1241859A1 (en) 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of gpr139
HK1241859B (en) 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of gpr139
BR112017010311B1 (pt) Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica compreendendo o mesmo, uso do referido composto ou sal farmaceuticamente aceitável do mesmo e combinação
EP3717450A1 (en) Compounds and methods for hematopoietic regeneration

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)